CVM - CEL-SCI Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
6.57
+0.28 (+4.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.29
Open6.45
Bid6.58 x 1000
Ask6.63 x 1100
Day's Range6.40 - 6.65
52 Week Range0.82 - 8.99
Volume533,332
Avg. Volume971,744
Market Cap221.428M
Beta (3Y Monthly)4.69
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1996-08-28
1y Target Est14.00
Trade prices are not sourced from all markets
  • Business Wire13 days ago

    CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

    CEL-SCI Corporation (NYSE American: CVM) announced that one of its key collaborators from Rush University Medical center, Dr. Adrienn Markovitz an Assistant professor in the department of Orthopedic Surgery, presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry in San Francisco, California on Wednesday July 3, 2019. The title of her presentation was “Vaccination with DerG LEAPS peptide conjugates incorporating distinct PG (aggrecan) epitopes protects by different immune mechanisms in the PG G1 domain induced mouse model of rheumatoid arthritis”.

  • These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
    Motley Fool28 days ago

    These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

    These stocks were huge winners last week. But can their momentum continue?

  • Zacks Small Cap Researchlast month

    CVM: No Free Samples on Facility Tour

    In late May 2019, Zacks was treated to an onsite tour of CEL-SCI’s (CVM) 73,000 square foot manufacturing facility in Elkridge, Maryland. As we drove to the industrial park southwest of Baltimore, we came upon CEL-SCI’s facility, nestled among warehouses and light manufacturing enterprises. With multiple delivery bays and administrative offices up front, we entered to meet with Chief Scientific Officer Dr. Eyal Talor who introduced us to the staff and provided background on the facility in preparation for our walk through.

  • Benzingalast month

    The Companies Set To Join The Russell Index July 1

    OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...

  • Business Wirelast month

    CEL-SCI Corporation Set to Join Russell 3000® Index

    CEL-SCI Corporation (NYSE American: CVM) is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • Business Wire2 months ago

    CEL-SCI Corporation to Present at the 9th Annual LD Micro Invitational

    CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 10:40 a.m. PT. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation. Mr. Kersten’s presentation will be webcast and available in the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.

  • Zacks Small Cap Research2 months ago

    CVM: Second Quarter 2019 Results

    By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reported fiscal second quarter 2019 results for the three month period ending March 31, 2019. A the end ...

  • Associated Press2 months ago

    Cel-Sci: Fiscal 2Q Earnings Snapshot

    The Vienna, Virginia-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 19 cents per share. The cancer immunotherapy company posted revenue of $150,800 ...

  • Business Wire2 months ago

    CEL-SCI Corporation Reports Second Quarter Fiscal 2019 Financial Results

    CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2019. The Company also reported key clinical and corporate developments achieved during the quarter.

  • Business Wire2 months ago

    CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting

    This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. CEL-SCI Corporation (NYSE American: CVM) announced today that Daniel Zimmerman, Ph.D., its Senior Vice President of Research, Cellular Immunology, presented new LEAPS data at the American Association of Immunologists 103th Annual Meeting (Immunology 2019) in San Diego, California on Saturday, May 11, 2019.

  • Business Wire2 months ago

    CEL-SCI Corporation Releases Letter to Shareholders

    The following letter was sent by CEL-SCI Corporation to its shareholders:

  • Business Wire3 months ago

    CEL-SCI to Present at the ThinkEquity Conference

    CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the ThinkEquity Conference in New York, NY on Thursday, May 2, 2019 at 1:00 p.m. A live audio webcast of the presentation and replay will be available on CEL-SCI's website at https://cel-sci.com/new-investor-information/. CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival.

  • Business Wire4 months ago

    CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

    CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization (CRO) responsible for data management of this Phase 3 study.

  • GlobeNewswire4 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CEL-SCI Corporation

    NEW YORK, March 26, 2019 -- Levi & Korsinsky announces it has commenced an investigation of CEL-SCI Corporation (NYSEAMERICAN: CVM) concerning possible breaches of.

  • Business Wire4 months ago

    CEL-SCI Selected by National Institutes of Health to Showcase Its LEAPS Technology at BIO International Convention

    CEL-SCI Corporation (NYSE American: CVM) today announced it has been selected by the U.S. National Institutes of Health (NIH) for sponsorship to exhibit and showcase its presentation for its LEAPS technology at the BIO International Convention, to be held June 3-6, 2019 in Philadelphia. LEAPS, which is currently being developed as a therapeutic vaccine for rheumatoid arthritis under a $1.5 million SBIR/STTR grant from the NIH, will be featured at the convention’s Innovation Zone, a turn-key exhibit space dedicated to showcasing select NIH SBIR/STTR awardees.

  • Business Wire5 months ago

    CEL-SCI’s Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical & Cellular Immunology

    CEL-SCI Corporation (NYSE American:CVM) today announced the Journal of Clinical & Cellular Immunology has published an article titled, “Why Don’t We Have a Vaccine Against Autoimmune Diseases?” co-written by Dr. Ken Rosenthal of Roseman University College of Medicine, and CEL-SCI’s Roy Carambula, Research Associate and Daniel Zimmerman Ph.D., Senior Vice President of Cellular Immunology.

  • Zacks Small Cap Research5 months ago

    CVM: Clinical Trials Update

    This assessment is based on historical event rates which suggests the final event will take place in the next few months. In CEL-SCI Corporation’s (CVM) a recent update to clinicaltrials.gov, we noticed that the anticipated completion was changed from December 2017 to December 2020. Management stated that the new anticipated completion date should read September 2019.

  • Associated Press5 months ago

    Cel-Sci: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Vienna, Virginia-based company said it had profit of 2 cents. Losses, adjusted for non-recurring gains, were 17 cents per share. The cancer immunotherapy company posted revenue ...

  • Business Wire5 months ago

    CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

    CEL-SCI Corporation today reported financial results for the quarter ended December 31, 2018.

  • Business Wire5 months ago

    CEL-SCI to Present at 2019 BIO CEO & Investor Conference

    CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the 2019 BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2018 at 2:00 p.m. A live audio webcast of the presentation and replay will be available on CEL-SCI's website at https://cel-sci.com/new-investor-information/. Now in its 21st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

  • Zacks Small Cap Research5 months ago

    CVM: CEL-SCI: Advancing with an Intent to Cure

    We are initiating coverage of CEL-SCI Corporation (CVM) with a $14.00 price target based on our estimates for a 2021 US and 2022 EU launch of lead compound Multikine in squamous cell carcinoma of the head and neck (SCCHN). The clinical-stage company is developing this biological product which contains multiple cytokines to enable the body to mount an anti-tumor immune response. The biologic is being developed as a first line therapy that will be administered to newly diagnosed, but not yet treated, head and neck cancer patients prior to their receiving standard of care (SOC), which includes surgery, chemotherapy and radiotherapy.

  • ACCESSWIRE6 months ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • Business Wire6 months ago

    U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

    CEL-SCI Corporation (NYSE American: CVM) today announced the U.S. Patent and Trademark Office has issued two new U.S. patents for the Company’s LEAPS platform technology. CEL-SCI’s LEAPS inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.

  • Business Wire6 months ago

    CEL-SCI Regains Full Listing Compliance with NYSE American

    CEL-SCI Corporation (NYSE American: CVM) today announced that it has received notification from the staff of the NYSE American, its current listing exchange, that the Company is now considered in full compliance with the continued listing requirements. The Company previously received notice on July 12, 2018, indicating that the Company was not in compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) of the listing requirements of the Exchange since it reported a stockholders’ equity deficit as of March 31, 2018 and had net losses in its 5 most recent fiscal years ended September 30, 2017.